ImmunoBrain, a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegenerative diseases, today announced that Phase 1b data for IBC-Ab002, a newly engineered ...

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and ...

A tumor “don’t‑eat‑me” shield also hides pro‑immune danger signals; new antibodies that unmask this hidden cue could make cancers more vulnerable to immune attack.

Study results suggest immune checkpoint inhibitor therapy may offer immunomodulatory benefits for patients with asthma and ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

Please provide your email address to receive an email when new articles are posted on . The consortium has enrolled approximately 1,000 patients with immune-related adverse events from checkpoint ...

Please provide your email address to receive an email when new articles are posted on . Education about immune-related adverse events associated with checkpoint inhibitor therapy for cancer is ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies. However, nearly half of patients show limited ...

Virus-associated cancers are a significant and persistent global health challenge, providing unique insight into the relationship between chronic infection ...

Immune system activation and activity is regulated through stimulatory or inhibitory ligand-receptor interactions collectively termed immune checkpoints. 1 Stimulatory interactions give the immune ...